Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart in Moderate to Severe Active Crohn's Disease
NCT05910528Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of afimkibart in Crohn's disease (2 arms), sponsored by Roche. Primary endpoint: Incidence of Treatment-Emergent Adverse Events (TEAE), Serious Adverse Events (SAE) and AE Leading to Discontinuation at 5 years. Started Jul 2023; status: active, not recruiting.
02
Drugs
afimkibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05910528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05910528.